Novartis Net Receivables from 2010 to 2025

NVS Stock  USD 97.53  0.33  0.34%   
Novartis Net Receivables yearly trend continues to be comparatively stable with very little volatility. Net Receivables will likely drop to about 8.8 B in 2025. From the period from 2010 to 2025, Novartis Net Receivables quarterly data regression had r-value of  0.01 and coefficient of variation of  19.44. View All Fundamentals
 
Net Receivables  
First Reported
2000-06-30
Previous Quarter
8.5 B
Current Value
8.2 B
Quarterly Volatility
2.2 B
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10 B, Interest Expense of 550.6 M or Selling General Administrative of 17.3 B, as well as many indicators such as Price To Sales Ratio of 3.86, Dividend Yield of 0.0241 or PTB Ratio of 3.23. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.
  
Check out the analysis of Novartis Correlation against competitors.

Latest Novartis' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Novartis AG ADR over the last few years. It is Novartis' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Very volatile
   Net Receivables   
       Timeline  

Novartis Net Receivables Regression Statistics

Arithmetic Mean9,188,092,255
Geometric Mean8,984,297,012
Coefficient Of Variation19.44
Mean Deviation1,209,744,277
Median9,073,000,000
Standard Deviation1,785,706,673
Sample Variance3188748.3T
Range8.1B
R-Value0.01
Mean Square Error3416064.5T
R-Squared0.0001
Significance0.97
Slope4,312,089
Total Sum of Squares47831224.8T

Novartis Net Receivables History

20258.8 B
20249.3 B
20238.1 B
20228.9 B
20218.8 B
20209.1 B
20198.6 B

About Novartis Financial Statements

Novartis shareholders use historical fundamental indicators, such as Net Receivables, to determine how well the company is positioned to perform in the future. Although Novartis investors may analyze each financial statement separately, they are all interrelated. The changes in Novartis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Novartis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables9.3 B8.8 B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.